Juvenile Dermatomyositis in Adolescents and Young Adults

  • Christina Ann BorosEmail author
Part of the In Clinical Practice book series (ICP)


Juvenile dermatomyositis (JDM) is a rare disease but the most common idiopathic inflammatory myopathy (IIM) of childhood. It is a systemic vasculopathy primarily affecting the skin and muscles, causing classic signs of rash and proximal muscle weakness, but can present with heterogeneous features, natural history and outcomes. This chapter highlights the differences between paediatric and adult disease in clinical presentation and presents an update of treatment strategies and outcomes of the disease including cardiovascular involvement, reproductive health and vocational developmental milestones.


Juvenile dermatomyositis Cardiovascular involvement Long-term outcomes Calcinosis 


  1. 1.
    Cattalini M, Soliani M, Caparello MC, Cimaz R. Sex differences in pediatric rheumatology. Clin Rev Allergy Immunol. 2017.
  2. 2.
    Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166–72.CrossRefGoogle Scholar
  3. 3.
    Boros C, McCann L, Ambrose N, Cortina-Borja M, Simou S, Pilkington C. Juvenile dermatomyositis: what comes next? Arthritis Rheumatol. 2016;68(Suppl 10).Google Scholar
  4. 4.
    Martin N, Krol P, Smith S, Beard L, Pilkington CA, Davidson J, et al. Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken). 2012;64(11):1665–72.CrossRefGoogle Scholar
  5. 5.
    Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther. 2013;15(2):211. Epub 2013/04/10CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–43.CrossRefGoogle Scholar
  8. 8.
    Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, et al. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis. 2015;74(1):204–10.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016;68(11):2806–16.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546–53.CrossRefGoogle Scholar
  12. 12.
    Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110–6.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, Subgroup CJM. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. Arthritis Rheumatol. 2018;70:785–93.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Campanilho-Marques R, Deakin CT, Simou S, Wedderburn LR, Pilkington C. Efficacy and safety of tumour necrosis factor antagonists in a large cohort of juvenile dermatomyositis patients [abstract]. Ann Rheum Dis. 2016;75(Suppl 2):140.CrossRefGoogle Scholar
  18. 18.
    Cabrera N, Duquesne A, Desjonqueres M, Larbre JP, Lega JC, Fabien N, et al. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open. 2016;2(2):e000271.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011;78(4):431–2.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436–46.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis. 2018;77(2):241–50.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.CrossRefGoogle Scholar
  23. 23.
    Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2014;66(5):732–40.CrossRefGoogle Scholar
  24. 24.
    Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open. 2016;2(2):e000291.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Papadopoulou C, Hong Y, Krol P, Y I, C P, H C, et al. The vasculopathy of Juvenile Dermatomyositis (JDM): evidence of persistent endothelial injury, hypercoagulability, subclinical inflammation and increased arterial stiffness. Arthritis Rheumatol. 2016;68(Suppl 10).Google Scholar
  26. 26.
    Chen JS, Roberts CL, Simpson JM, March LM. Pregnancy outcomes in women with rare autoimmune diseases. Arthritis Rheumatol. 2015;67(12):3314–23.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Women’s and Children’s HospitalAdelaideAustralia
  2. 2.University of AdelaideAdelaideAustralia

Personalised recommendations